The Joint Corp Q2 revenue beats estimates, reiterates 2026 outlook
The Joint Corp Q2 revenue beats estimates, reiterates 2026 outlook
Overview
US chiropractic clinic franchisor's Q2 revenue rose 14%, beating analyst expectations
Adjusted EBITDA from continuing operations increased sharply year-over-year
Company repurchased $677,000 in shares and completed three regional developer territory buybacks
Outlook
Company reiterates 2026 system-wide sales guidance of $519 mln to $552 mln
Company expects 2026 consolidated Adjusted EBITDA of $12.5 mln to $13.5 mln
New franchised clinic openings for 2026 now seen at 22 to 26, excluding refranchised clinics
Result Drivers
FRANCHISOR MODEL SHIFT - Co said revenue growth reflected transition to pure-play franchisor model and clinic portfolio optimization
PATIENT RETENTION - Co said increased adoption of flexible plan options drove stronger patient retention
OPERATING EFFICIENCY - Co said refranchising and streamlined structure improved operating efficiency and free cash flow
Company press release: ID:nGNX9Vnkp
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $15.2 mln | $14.57 mln (4 Analysts) |
Q2 EPS |
| $0.05 |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Joint Corp is $9.00, about 8% above its August 5 closing price of $8.33
The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 37 three months ago
Reuters Recommended Reads
Aug 5 - US Physical Therapy Q2 revenue rises on higher patient volume
Aug 6 - Restaurant Brands International Q2 system-wide sales rise, led by Burger King
Aug 6 - Planet Fitness Q2 revenue beats; reiterates 2026 revenue growth
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Joint
See all newsBrief: Joint Corp To Reacquire Texas Regional Development Rights And Terminate Related Agreements
Brief: Joint Corp. To Close Underperforming Clinics In 2026
Joint Corp reports results for the quarter ended June 30 - Earnings Summary
The Joint Corp Q2 revenue beats estimates, reiterates 2026 outlook
Brief: Joint Q2 EPS USD 0.05